Intervention: Betamethasone
Trial phase: Phase 2
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Patients will be followed at 1 week after Ozurdex insertion (0.7 mg) and then at 1,2, 3,4, 5, and 6 months. Afterwards, patients will be seen every 2 months. At each visit patients will undergo measurement of BCVA, complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Each eye in the Ozurdex group can have a maximum total of three Ozurdex insertions at minimum of 4-month intervals in the first year of study.

The criteria for retreatment with Ozurdex are:

i.The study eye must have shown initial favorable response to prior Ozurdex implant (>10% decrease in central macular thickness with maintenance [change in BCVA of <=1 line] or improvement of visual acuity [increase of BCVA of >1 line]) ii. Interval since last Ozurdex implant should be > 4 and < 12 months. iii. The study eye must show definite evidence of recurrence of macular edema.
Eligibility criteria:
Inclusion criteria:

Patient age 18 years or more.
Uveal melanoma treated with I-125 plaque radiotherapy.
Visual acuity between 20/40 to 20/400 secondary to post-radiation macular edema.
Central subfield retinal thickness > 300 micron.
Duration of macular edema < 12 months.
No potential contributing causes of decreased vision other than macular edema.

Exclusion criteria:

Visual acuity worse than 20/400 or better than 20/40.
Monocular patient or poor vision in the non-study eye (<20/80).
History of vitrectomy surgery.
Panretinal photocoagulation or intraocular surgery within 3 months of enrollment.
Concomitant or previous radiation optic neuropathy.
Use of periocular, intravitreal, or systemic steroids within 6 month of enrollment in the study eye.
Use of intravitreal VEGF antagonist within 6 weeks of enrollment.
History of ocular hypertension or glaucoma, or intraocular pressure (IOP)>21 mmHg.
History of steroid-induced glaucoma in either eye.
Active ocular infection or history of herpetic eye infection.
Clinically significant epiretinal membrane in the study eye.
Iris neovascularization in the study eye.
Clinically significant media opacity preventing acquisition of good-quality optical coherence tomography (OCT) in the study eye.
Aphakia or anterior chamber intraocular lens.
Poorly controlled diabetes (Hemoglobin A1c level >13%).
Poorly controlled hypertension (Systolic pressure > 160 mm Hg or diastolic pressure > 90 mm Hg).
Pregnancy (women of childbearing age should have negative pregnancy test and use contraception).
Presence of any ocular condition that in the opinion of one of the investigators will prevent at least 2 lines of improvement in best-corrected visual acuity.
Interval between plaque radiotherapy for uveal melanoma and intended date of dexamethasone intravitreal implant of less than 6 months.
Evidence of activity or inadequate regression of the treated uveal melanoma after plaque radiotherapy (based on the judgment of the study investigators).
Known allergy or hypersensitivity to any of the study medications or their components.
History of prior myocardial infarction or stroke.